1. NAME OF THE MEDICINAL PRODUCT

ZADOMAX Ketotifen Fumarate 0.025% Eye drops

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

[API and strength:

Each ml of Zadomax eye drop

solution contains:

Ketotifen Fumarate

0.025%w/v

Excipients with known effect:

Each 5ml contains 1.25mg/ml of Benzalkonium Chloride.

{For a full list of excipients, see section 6.1}

3. PHARMACEUTICAL FORM

Eye drops, solution. Zadomax Relief is a clear and colourless solution of Ketotifen fumarate with a pH of 5.0-6.0.

4. Clinical particulars

4.1 Therapeutic indications

Zadomax Relief Eye Drops (Ketotifen 0.025%), Eye Drops is indicated in symptomatic treatment of seasonal allergic conjunctivitis.

4.2 Posology and method of administration

Posology

Adults, elderly, and children (age 3 and older): one drop of Zadomax Relief into the conjunctival sac twice a day.

Paediatric population

The safety and efficacy of Zadomax Relief in children aged from birth to 3 years have not yet been established.

Method of administration

The contents and dispenser remain sterile until the original closure is broken. To avoid contamination do not touch any surface with the dropper tip.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1.

4.4 Special warnings and precautions for use

This medicine contains benzalkonium chloride.

Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. Remove contact lenses prior to application and wait at least 15 minutes before reinsertion.

Benzalkonium chloride may also cause eye irritation, especially in dry eyes or disorders of the cornea.

4.5 Interaction with other medicinal products and other forms of interaction

Zadomax is used concomitantly with other eye medications. There must be an interval of at least 5 minutes between the two medications.

The use of oral dosage forms of ketotifen may potentiate the effect of CNS depressants, antihistamines, and alcohol. Although this has not been observed with Zadomax Relief eye drops, the possibility of such effects cannot be excluded.

4.6 Pregnancy and Lactation

Pregnancy
There are no adequate data from the use of ketotifen eye drops in pregnant women. Animal studies using maternally toxic oral doses showed increased pre- and postnatal mortality, but no teratogenicity. Systemic levels after ocular administration are much lower than after oral use. Caution should be exercised when prescribing to pregnant women.

Lactation
Although animal data following oral administration show excretion into breast milk, topical administration to humans is unlikely to produce detectable quantities in breast milk. Zadomax eye drops can be used during lactation.

Fertility
here are no data available on the effect of ketotifen fumarate on fertility in humans.

4.7 Effects on ability to drive and use machines.

Any patient on Zadomax Relief Eye Drops, Ketotifen 0.025% that experiences blurred vision or somnolence should not drive or operate machines.

4.8 Undesirable effects

Immune system disorders

Uncommon: Hypersensitivity

Nervous system disorders

Uncommon: Headache

Eye disorders

Common: Eye irritation, eye pain, punctate keratitis, punctate corneal epithelial erosion.

Uncommon: Vision blurred (during instillation), dry eye, eyelid disorder, conjunctivitis, photophobia, conjunctival haemorrhage.

Gastrointestinal disorders

Uncommon: Dry mouth

Skin and subcutaneous tissue disorders

Uncommon: Rash, eczema, urticaria

General disorders and administration site conditions

Uncommon: Somnolence

Adverse drug reactions from post-marketing experience (Frequency not known):

The following post marketing events have also been observed: hypersensitivity reactions including local allergic reaction (mostly contact dermatitis, eye swelling, eyelid pruritis and oedema), systemic allergic reactions including facial swelling/oedema (in some cases associated with contact dermatitis) and exacerbation of pre-existing allergic conditions such as asthma and eczema.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme

4.9 Overdose

No cases of overdose have been reported.

Clinical results have shown no serious signs or symptoms after oral ingestion of up to 20 mg of ketotifen.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamics properties

Pharmacotherapeutic group: Ophthalmological, other anti-allergics, ATC code: S01GX08

Mechanism of action>
Ketotifen is a histamine H1-receptor antagonist. In vivo animal studies and in vitro studies suggest the additional activities of mast cell stabilization and inhibition of infiltration, activation and degranulation of eosinophils.

5.2 Pharmacokinetic properties

In a pharmacokinetic study conducted in 18 healthy volunteers with Zadomax Relief eye drops, plasma levels of ketotifen after repeated ocular administration for 14 days were in most cases below the limit of quantitation (20 µg/ml).

After oral administration, ketotifen is eliminated biphasically with an initial half-life of 3 to 5 hours and a terminal half-life of 21 hours. About 1% of the substance is excreted unchanged in the urine within 48 hours and 60 to 70% as metabolites. The main metabolite is the practically inactive ketotifen-N-glucuronide.

5.3 Non-Clinical Data properties

Preclinical data reveal no special hazard which is considered relevant in connection with use of Zadomax Relief eye drops in humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

[List all excipients **except solvents removed during processing**.]

- Benzalkonium chloride
- Glycerine
- Sodium hydroxide
- Disodium Edetate
- HCl
- Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in Section 6.6.>

6.3 Shelf life

In unopened bottle: 2 years
After opening: 4 Weeks

6.4 Special precautions for storage

Do not store it above 25 °C and away from light and in the provided carton.

6.5 Nature and contents of container <and special equipment for use, administration, or implantation>

The container is a white-coloured LDPE bottle with an opaque LDPE dropper bottle and a white HDPE screw cap with an integrated safety ring. One bottle contains 5 ml of the solution.

6.6 Special precautions for disposal and other handling

No special requirements.
Any unused product or waste material should be disposed of in accordance with local requirements.

7. <APPLICANT/MANUFACTURER

FIDSON HEALTHCARE PLC

17-21 Fidson Avenue,
Sango-Ota, Ogun State.
Nigeria.